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Summary. In assessing the optimal intensity of anticoagulant
therapy, the International Normalized Ratio (INR) at admis-
sion is used äs a basis for INR-specific incidence rates. In 47
patients suffering a haemorrhagic stroke we tested the
assumption that the INR at admission is an acceptable
measure for the INR that preceded the haemorrhage. We
found high D-dimer levels in 70% of the patients, which
indicated activated coagulation and fibrinolysis. This was not
of such an extent that it could also be measured with other
routine coagulation tests, with the possible exception of two
patients. We found normal INRs in 33 non-anticoagulated
patients, and only a mildly prolonged INR of 1-9 in one
patient, which was most probably caused by a vitamin K
deficiency. We concluded that the INR at admission can be
used in studies to assess the optimal level of anticoagulation.
Keywords: oral anticoagulant therapy, cerebral bleeding,
consumption coagulopathy, INR, optimal intensity.
Oral anticoagulant therapy is effective in the prevention of
thromboembolism. An important adverse effect is the
increased risk of cerebral bleeding. We developed a method
to study the optimal intensity of anticoagulant therapy, i.e.
the intensity (expressed in International Normalized Ratio,
INR) at which both thromboembolism and bleeding are
minimal (Rosendaal et al, 1993). With this method,
intensity-specific incidence rates of all adverse events are
calculated äs the ratio of the total number of events which
take place at a certain level of anticoagulation and the
number of patient-years that this level was achieved by the
total patient population. This method has been successfully
applied in a number of studies (Azar et al, 1996; EAFT study
group, 1995; Cannegieter et al, 1995; van der Meer et al, 1993).
These results are all based on the assumption that the INR
measured at admission - often several hours after the
Symptoms started - corresponds to the INR just before the
event and is not a consequence of the bleeding.
Several papers have reported coagulation disorders after
head injury which in some cases resulted in severe
disseminated intravascular coagulation (DIC) (Sande et al,
Correspondence: Dr E R. Rosendaal, Department of Clinical
Epidemiology, Bldg l, CO-P, University Hospital Leiden, P.O. Box
9600, 2300 RC Leiden, The Netherlands.
© 1997 Blackwell Science Ltd
1978; Touho et al, 1986). This may be explained by the release
of tissue factor from damaged brain tissue into the circulation,
which will activate coagulation and secondary fibrinolysis. In
patients suffering a stroke, the same mechanism, though less
prominent, may be involved in the progression of the stroke. In
a number of studies low-grade DIC has been described in stroke
patients (Lane et al, 1983; van Wersh & Franke, 1993; Landi
et al, 1987). Especially in anticoagulated~patients, a slight
activaüon of coagulation may cause further consumption of the
vitamin K dependent clotting factors which are already present
in a low concentration. This can result in a higher INR at
admission than at the Start of the Symptoms. If this is the case,
the INR at admission is not a reliable measure on which to base
INR-specific incidence rates, which implies that the results of
studies that use this method are invalid. Therefore we studied
the assumption that the INR at admission is an acceptable
measure for the INR that preceded the haemorrhage.
METHODS
Forty-seven consecutive patients with an intracranial bleed-
ing and who were hospitalized within 24 h of the onset of
Symptoms took part in the study. Patients were excluded if no
Computer tomography scan of the brain was performed or no
blood sample was obtained before any therapy was given. In
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Table l. Results of coagulation and fibrinolysis markers.
Oral anticoagulant treatment
Tests
Platelets (xl09/l)
APTT (s)
PT(s)
INR
FVIIIx (lü/ml)
FV (%)
Fibrinogen (g/l)
D-dimer (ng/ml)
Yes (n = 13)
mean (ränge)
237(164-333)
38.3 (27-9-46-7)
33.4(23-9-42-5)
3.8 (2-5-5-1)
2.28 (1-37-3-12)
104 (84-130)
4.7(2-8-8-6)
312(29-1022)4
No (n = 34)
mean (ränge)
245 (147-387)
25.1 (19-4-35-9)1
11.7(10-l-19-6)2
1.0(0-8-l-9)2
1.92 (0-39-3-06)3
113 (74-162)
3.1 (1-7-5-3)
295 (21-1978)5
Reference ranges
150-400
25.0-33-0
11.5-14-5
0.9-1-3
0.65-1-35
0.75-125
1.7-4-5
0-80
1
 Three patients exceeded the upper limit of the reference ränge.
2
 One patient exceeded the upper limit of the reference ränge.
3
 One patient had a FVni:c under the lower limit.
4
 Nine patients exceeded the upper limit of the reference ränge.
5
 23 patients exceeded the upper limit of the reference ränge.
addition to patients with oral anticoagulant therapy, we also
included patients without this treatment to compare the
extent of the activation of the coagulation.
Activated partial thromboplastin time was measured with
Cephotest (Nycomed, Oslo, Norway), prothrombin time with
Thromborel S (Behringwerke AG, Marburg, Germany), and
was also expressed äs INR (International Normalized Ratio).
Fibrinogen concentration was derived from the prothrombin
time. Fibrinogen degradation products were measured with
TintElize® D-dimer (Biopool, Umea, Sweden). Factor VIII
coagulant activity (FVÜI:c) was measured with Automated
APTT (Organon Teknika, Durham, U.S.A.) and FVHI-
deficient plasma. Factor V coagulant activity was measured
with Thromborel S (Behringwerke AG, Marburg, Germany)
and FV-deficient plasma. Platelets were counted with a
Coulter counter. Laboratory reference values were obtained
from 78 healthy volunteers, age ränge 20-60 years.
To study whether differences in coagulation parameters
might depend on the type of bleeding, we classified the bleed
äs subdural, subarachnoidal or intracerebral. For the same
reason, we categorized the severity of the haemorrhage äs:
(1) fatal within 30 d; (2) residual effects; (3) füll recovery.
RESULTS
Table I shows the results of the haemostatic tests in the 47
patients. 13 patients received anticoagulant therapy for
various reasons. In four patients the INR was not in the
therapeutic ränge at admission: in two it was above, and in
two it was below the normal ränge. The APTT was prolonged
in most anticoagulated patients. The values of the other
coagulation tests were normal, with the exception of the D-
dimer essay.
In the 34 non-anticoagulated patients, all values of the
platelet count, factor V activity and fibrinogen were in the
normal ranges. In three patients the APTT was marginally
prolonged (34-0-35-9 s), and in one of these patients the PT
was also mildly prolonged (19-6 s). This last patient also had
an elevated INR (1-9). In another patient (APTT 34-Os,
normal PT), factor VIII:c was low at 0-39 lU/ml.
FVIILc was high in the majority of the patients (72%
had activity > l-70IU/ml) and was found in both the
anticoagulated and the non-anticoagulated groups. High
D-dimer levels were found (> 80 ng/ml) in 32 patients (68%).
This percentage was the same for patients with and without
anticoagulant treatment.
Table II summarizes the clinical results. All events but one
had occurred spontaneously. Mortality was higher for
patients on anticoagulant treatment: 60% died, compared
to 29% of the patients without anticoagulant treatment. No
Table II. Patient characteristics.
Oral anticoagulant treatment
Age (years)
<50
50-69
3=70
Sex
Men
Women
Type
Subarchnoidal
Intracerebral
Subdural
Severity
Fatal
Residual effects ,
Füll recovery
Yes (n = 13)
n (%)
0(0)
5(38)
8(62)
8(62)
5(38)
1(8)
11(85)
1(8)
10 (60)
2(15)
0(0)
No (n =34)
n (%)
8(24)
16 (47)
10 (29)
19 (56)
14(41)
7(21)
26 (76)
0(0)
10 (29)
21 (62)
3(9)
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differences in haemostatic tests could be demonstrated
between patients with a fatal or a non-fatal bleeding, with
the exception of D-dimer levels. In eight patients very high
D-dirner levels were found (> 500ng/ml), whereas all other
factors were within the normal ränge. Seven of these
patients died äs a result of the bleeding. The three types of
haemorrhage differed also in D-dimer levels only: mean D-
dimer in patients with subarachnoidal bleeding was 638 ng/
ml whereas in patients with intracerebral bleeding this was
219ng/ml.
DISCUSSION
Normal routine coagulation tests were found in the majority
of 47 consecutive patients with intracranial bleeding. Three
non-anticoagulated patients had a slightly prolonged APTT.
In the first of these three the PT was also slightly prolonged
although all other parameters were normal. Since coumarin
therapy was denied at admission, the most probable
explanation is vitamin K deficiency. A consumption coagulo-
pathy is unlikely since all other parameters were normal,
including D-dimer. A second patient, a young man aged 36
years, had a low FVIII:c of 0-39 lU/ml which explained his
slightly prolonged APTT. Several months later his FVIH:c
was normal. Even though all other parameters were normal
at admission, coagulation activation may be likely. In the
third patient no other abnormalities were found, with the
exception of elevated D-dimer levels. So, in this case 5t may
also be concluded that the prolonged APTT was caused by a
mild consumption coagulopathy.
A remarkable finding was the high levels of FVIItc in most
patients. Almaani et al (1987) found an association between
high FVIII:Ag and mortality in 42 patients with intracranial
haemorrhage. Landi et al (1987) also reported higher FVIHx
in stroke patients who died than in survivors. We did not find
an association with mortality nor with abnormalities in the
other coagulation parameters.
We found high D-dimer levels in about 70% of the
patients. Van Wersch & Franke (1993) also found elevated D-
dimer levels in 27/34 patients with cerebral haemorrhage.
The high D-dimer levels indicate activated coagulation and
fibrinolysis in patients with a cerebral haemorrhage, which
is not of such an extent that it can also be measured with
other routine coagulation tests, such äs in DIC. In this series
of 47 patients this was possibly the case in two patients only;
however, this did not affect the INR. We found normal INRs
in 33 non-anticoagulated patients, and only a mildly
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prolonged INR of 1-9 in one patient, which was most likely
brought about by vitamin K deficiency.
The aim of this study was to test the assumption that the
INR at admission is an adequate measure for the INR at the
start of the bleeding and not a result of the bleeding. We
conclude that this is a valid assumption and that the INR at
admission can therefore be used in studies to assess the
optimal level of anticoagulation.
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